Regencell Bioscience (NASDAQ:RGC) Releases Quarterly Earnings Results

Regencell Bioscience (NASDAQ:RGC) released its quarterly earnings results on Friday. The company reported $0.00 EPS for the quarter, FiscalAI reports.

Regencell Bioscience Trading Down 7.0%

NASDAQ:RGC traded down $2.19 during midday trading on Friday, reaching $29.28. The company had a trading volume of 95,186 shares, compared to its average volume of 106,420. The stock’s fifty day simple moving average is $27.18 and its 200-day simple moving average is $23.85. Regencell Bioscience has a 12-month low of $6.13 and a 12-month high of $83.60.

Institutional Trading of Regencell Bioscience

Institutional investors have recently bought and sold shares of the business. Seven Fleet Capital Management LP purchased a new stake in Regencell Bioscience during the 4th quarter worth about $92,000. Hudson Bay Capital Management LP purchased a new stake in Regencell Bioscience during the 4th quarter worth about $275,000. Vident Advisory LLC lifted its holdings in Regencell Bioscience by 65.7% during the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock worth $629,000 after buying an additional 11,866 shares during the last quarter. XTX Topco Ltd purchased a new stake in Regencell Bioscience during the 3rd quarter worth about $598,000. Finally, BNP Paribas Financial Markets purchased a new stake in Regencell Bioscience during the 2nd quarter worth about $768,000. 0.13% of the stock is owned by hedge funds and other institutional investors.

More Regencell Bioscience News

Here are the key news stories impacting Regencell Bioscience this week:

• Positive Sentiment: Regencell reported quarterly EPS of $0.00, which removes near-term earnings disappointment, though it does not provide a strong growth catalyst. MarketBeat earnings report
• Neutral Sentiment: Multiple law firms reiterated deadlines for investors in an existing class action tied to Regencell securities purchased between October 28, 2024 and October 31, 2025. These notices mainly update shareholders on legal options rather than company operations. Pomerantz class action filing
• Neutral Sentiment: Other firms, including Rosen, Schall, Faruqi & Faruqi, and Glancy Prongay Wolke & Rotter, continued reminding investors of the June 23, 2026 lead-plaintiff deadline, adding to legal overhang but not introducing new operational news. Schall Law Firm notice
• Negative Sentiment: The biggest drag on RGC appears to be the ongoing securities-fraud litigation and related investor-loss marketing, which can weigh on sentiment and increase uncertainty around the stock. Robbins LLP notice

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.